Promising Results from Sickle Cell Disease Bone Marrow Transplant Pilot Study - European Medical Journal

Promising Results from Sickle Cell Disease Bone Marrow Transplant Pilot Study

1 Mins
Hematology

BONE MARROW transplantation was the subject of a recent pilot study investigating a prophylactic regimen both for matched sibling donors and unrelated donors for treatment of adults with sickle cell disease (SCD). The results of the study showed comparable overall and event-free survival rates in patients between the two donor types, exceeding 90% and 85%, respectively, after 1 year, and have led to the development of the STRIDE study, a Phase II single-arm, multicentre trial.

The pilot study enrolled 22 SCD patients aged 17–36 years across 8 different sites. Of these, 17 patients received a transplantation from a sibling-matched donor and 5 patients received marrow from an unrelated donor. Non-myeloablative conditioning in SCD patients with matched-sibling bone marrow transplant was found to be effective, whereas a higher intensity regimen of busulfan, fludarabine, and antithymocyte globulin showed efficacy in unrelated-donor transplantation for other conditions. In addition to this, the 3-year event-free survival of patients was measured as 82%, health-related quality of life also improved with statistical significance.

The resulting Phase II trial STRIDE will investigate the effects of a reduced toxicity preparative regimen on graft-versus-host disease prophylaxis in adults with SCD. Overall survival at 2 years from biologic assignment is the primary endpoint. Lakshmanan Krishnamurti, Children’s Healthcare, Atlanta/Emory University, Atlanta, Georgia, USA, explained: “Chronic GVHD is higher in patients aged 16–30 versus patients 15 and younger,” adding “Age is an important predictor of outcomes and the risk for progressive morbidity-impaired quality of life and risk of mortality still exists in adults with sickle cell disease.”

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now